通过非热气等离子体调节程序性死亡配体 1 的表达，提高乳腺癌细胞对阿特珠单抗的敏感性

IF 2.9 3区物理与天体物理 Q2 PHYSICS, APPLIED

Plasma Processes and Polymers Pub Date : 2024-07-01 DOI:10.1002/ppap.202400072

Shweta B. Borkar, Paritosh Patel, Manorma Negi, Tirtha Raj Acharya, Neha Kaushik, Eun Ha Choi, Nagendra K. Kaushik

{"title":"通过非热气等离子体调节程序性死亡配体 1 的表达，提高乳腺癌细胞对阿特珠单抗的敏感性","authors":"Shweta B. Borkar, Paritosh Patel, Manorma Negi, Tirtha Raj Acharya, Neha Kaushik, Eun Ha Choi, Nagendra K. Kaushik","doi":"10.1002/ppap.202400072","DOIUrl":null,"url":null,"abstract":"The aggressiveness and limited treatment options make triple‐negative breast cancer (TNBC) a challenging condition to treat. Immune checkpoint blockade therapy, explicitly targeting the programmed death‐ligand 1 (PD‐L1) pathway, is a promising therapeutic approach. However, the effectiveness of PD‐L1 inhibitors like atezolizumab depends on adequate PD‐L1 expression within cancer cells. To this end, this study used nonthermal plasma (NTP) to modulate PD‐L1 in TNBC cells. The current investigation revealed that NTP treatment leads to an upregulation of PD‐L1; this might increase the availability of PD‐L1 to PD‐L1 inhibitors. These findings suggest that shortly NTP could be used as an adjunctive treatment to immunotherapy in TNBC cells.","PeriodicalId":20135,"journal":{"name":"Plasma Processes and Polymers","volume":"31 1","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Modulation of programmed death‐ligand 1 expression to augment sensitivity to atezolizumab in breast cancer cells through nonthermal air gas plasma\",\"authors\":\"Shweta B. Borkar, Paritosh Patel, Manorma Negi, Tirtha Raj Acharya, Neha Kaushik, Eun Ha Choi, Nagendra K. Kaushik\",\"doi\":\"10.1002/ppap.202400072\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The aggressiveness and limited treatment options make triple‐negative breast cancer (TNBC) a challenging condition to treat. Immune checkpoint blockade therapy, explicitly targeting the programmed death‐ligand 1 (PD‐L1) pathway, is a promising therapeutic approach. However, the effectiveness of PD‐L1 inhibitors like atezolizumab depends on adequate PD‐L1 expression within cancer cells. To this end, this study used nonthermal plasma (NTP) to modulate PD‐L1 in TNBC cells. The current investigation revealed that NTP treatment leads to an upregulation of PD‐L1; this might increase the availability of PD‐L1 to PD‐L1 inhibitors. These findings suggest that shortly NTP could be used as an adjunctive treatment to immunotherapy in TNBC cells.\",\"PeriodicalId\":20135,\"journal\":{\"name\":\"Plasma Processes and Polymers\",\"volume\":\"31 1\",\"pages\":\"\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Plasma Processes and Polymers\",\"FirstCategoryId\":\"101\",\"ListUrlMain\":\"https://doi.org/10.1002/ppap.202400072\",\"RegionNum\":3,\"RegionCategory\":\"物理与天体物理\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHYSICS, APPLIED\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Plasma Processes and Polymers","FirstCategoryId":"101","ListUrlMain":"https://doi.org/10.1002/ppap.202400072","RegionNum":3,"RegionCategory":"物理与天体物理","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHYSICS, APPLIED","Score":null,"Total":0}

引用次数: 0

摘要

三阴性乳腺癌（TNBC）的侵袭性和有限的治疗选择使其成为一种具有挑战性的疾病。免疫检查点阻断疗法明确针对程序性死亡配体1（PD-L1）途径，是一种很有前景的治疗方法。然而，阿特珠单抗等PD-L1抑制剂的疗效取决于癌细胞内PD-L1的充分表达。为此，本研究使用非热等离子体（NTP）来调节 TNBC 细胞中的 PD-L1。目前的调查显示，NTP 处理会导致 PD-L1 的上调；这可能会增加 PD-L1 对 PD-L1 抑制剂的可用性。这些研究结果表明，短效 NTP 可作为 TNBC 细胞免疫疗法的辅助疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Modulation of programmed death‐ligand 1 expression to augment sensitivity to atezolizumab in breast cancer cells through nonthermal air gas plasma

The aggressiveness and limited treatment options make triple‐negative breast cancer (TNBC) a challenging condition to treat. Immune checkpoint blockade therapy, explicitly targeting the programmed death‐ligand 1 (PD‐L1) pathway, is a promising therapeutic approach. However, the effectiveness of PD‐L1 inhibitors like atezolizumab depends on adequate PD‐L1 expression within cancer cells. To this end, this study used nonthermal plasma (NTP) to modulate PD‐L1 in TNBC cells. The current investigation revealed that NTP treatment leads to an upregulation of PD‐L1; this might increase the availability of PD‐L1 to PD‐L1 inhibitors. These findings suggest that shortly NTP could be used as an adjunctive treatment to immunotherapy in TNBC cells.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Plasma Processes and Polymers 物理-高分子科学

CiteScore

6.60

自引率

11.40%

发文量

150

审稿时长

3 months

期刊介绍： Plasma Processes & Polymers focuses on the interdisciplinary field of low temperature plasma science, covering both experimental and theoretical aspects of fundamental and applied research in materials science, physics, chemistry and engineering in the area of plasma sources and plasma-based treatments.